Amanda Smith is a freelance journalist and writer. She reports on culture, society, human interest and technology. Her stories hold a mirror to society, reflecting both its malaise and its beauty.

Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug Repatha (evolocumab). In August 2025, the US Food and Drug ...

Amgen AMGN is off to a strong start in 2025 with its first-quarter earnings as well as sales beating estimates. Particularly, its strong top-line performance caught investor attention. Amgen’s total ...

Amgen Inc. (AMGN) reported strong Q4 2025 results and provided full-year 2026 guidance that was above Street expectations. The company is managing losses of exclusivity on several large products quite ...

Amgen AMGN reported fourth-quarter 2025 adjusted earnings of $5.29 per share, which beat the Zacks Consensus Estimate of $4.76 per share. Earnings were relatively flat year over year as higher ...

The Trump administration launched a new website, TrumpRx, to offer Americans discounts on prescription drugs. The program aims to lower drug costs through "most-favored-nation-pricing" deals with ...

The new website promises “low cost prescription drugs,” but will not prescribe or sell drugs directly to the patient Dimitrios Kambouris/Getty The Trump administration has announced that its discount ...

Weight loss candidates from Amgen and Roche performed well in phase 2 studies. These could be exciting additions to these companies' drug portfolios. Both drugmakers have attractive lineups and deep ...